Structural difference in the complement activation site of human IgG1 and IgG3
- PMID: 19906198
- DOI: 10.1111/j.1365-3083.2009.02338.x
Structural difference in the complement activation site of human IgG1 and IgG3
Abstract
The C1q binding epicentre on IgG molecules involves residues Asp(270), Lys(322), Pro(329) and Pro(331) in the C(H)2 domain. IgG1 and IgG3 are usually the most efficient of the four human IgG subclasses in activating complement and they both share all these residues. To reveal possible differences in the structural requirement for complement activation, we created a number of NIP (5-iodo-4-hydroxy-3-nitro-phenacetyl) specific IgG1 and IgG3 antibodies with parallel mutations in or near the putative C1q binding site. The mutants were tested simultaneously for antibody induced, antibody-dependent complement-mediated lysis (ADCML) at high and low antigen concentration on the target cells using sera of human, rabbit and guinea pig as complement source. In addition, we tested the antibodies against target cells decorated with the NP hapten, which has 10-fold lower affinity for the antibodies compared to the NIP hapten. We also used ELISA methods to measure complement activation. We observed a clear difference between IgG1 and IgG3 localized to residues Asp(270), Leu(334), Leu(335). For all these residues, and especially for Asp(270), IgG1 was heavily reduced in complement activation, while IgG3 was only moderated reduced, by alanine substitution. This difference was independent of the long hinge region of IgG3, demonstrated by hinge region truncation of this isotype such that it resembles that of IgG1. This report indicates the presence of structural differences between human IgG1 and IgG3 in the C1q binding site, and points to a specialization of the two isotypes with respect to complement activation.
Similar articles
-
A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells.Eur J Immunol. 2006 Jan;36(1):129-38. doi: 10.1002/eji.200535178. Eur J Immunol. 2006. PMID: 16323243
-
Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.Mol Immunol. 2000 Nov;37(16):995-1004. doi: 10.1016/s0161-5890(01)00010-4. Mol Immunol. 2000. PMID: 11395138
-
The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.Immunology. 1995 Oct;86(2):319-24. Immunology. 1995. PMID: 7490135 Free PMC article.
-
The structural requirements for complement activation by IgG: does it hinge on the hinge?Immunol Today. 1995 Feb;16(2):85-90. doi: 10.1016/0167-5699(95)80094-8. Immunol Today. 1995. PMID: 7888072 Review.
-
Antibody-mediated regulation of the immune response.Scand J Immunol. 2006 Sep;64(3):177-84. doi: 10.1111/j.1365-3083.2006.01818.x. Scand J Immunol. 2006. PMID: 16918684 Review.
Cited by
-
Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein.Infect Immun. 2012 Jan;80(1):187-94. doi: 10.1128/IAI.05956-11. Epub 2011 Nov 7. Infect Immun. 2012. PMID: 22064712 Free PMC article.
-
Impact of structural modifications of IgG antibodies on effector functions.Front Immunol. 2024 Jan 8;14:1304365. doi: 10.3389/fimmu.2023.1304365. eCollection 2023. Front Immunol. 2024. PMID: 38259472 Free PMC article. Review.
-
Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.Diabetes. 2011 Feb;60(2):582-9. doi: 10.2337/db10-0915. Epub 2010 Oct 27. Diabetes. 2011. PMID: 20980456 Free PMC article. Clinical Trial.
-
Avidity in antibody effector functions and biotherapeutic drug design.Nat Rev Drug Discov. 2022 Oct;21(10):715-735. doi: 10.1038/s41573-022-00501-8. Epub 2022 Jul 5. Nat Rev Drug Discov. 2022. PMID: 35790857 Free PMC article. Review.
-
A pilot study showing differences in glycosylation patterns of IgG subclasses induced by pneumococcal, meningococcal, and two types of influenza vaccines.Immun Inflamm Dis. 2014 Aug;2(2):76-91. doi: 10.1002/iid3.22. Epub 2014 May 22. Immun Inflamm Dis. 2014. PMID: 25400928 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous